Electromyography (EMG) and Nerve Conduction Studies

Electromyography (EMG) and nerve conduction studies (NCS) are electrodiagnostic tests that measure the electrical activity of muscles and the speed of signal transmission along peripheral nerves. Together, they form a paired diagnostic protocol used across neurology and neuromuscular medicine to localize dysfunction within the peripheral nervous system. Understanding how these tests are structured, what they detect, and where their diagnostic limits lie is essential context for patients, clinicians, and administrators navigating neurological care. The regulatory and coverage frameworks governing these procedures shape how and when they are ordered.

Definition and Scope

Electromyography records the electrical potentials generated by muscle fibers at rest and during voluntary contraction. Nerve conduction studies, performed as a complement or standalone procedure, measure how quickly and how strongly electrical impulses travel through specific peripheral nerves. The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) defines the combined EMG/NCS evaluation as the standard electrodiagnostic examination for neuromuscular disease, distinguishing it from other neurophysiologic tests such as the electroencephalogram (EEG), which targets central nervous system electrical activity.

The scope of EMG/NCS extends across the full peripheral nervous system: motor neurons in the anterior horn of the spinal cord, nerve roots, plexuses, individual peripheral nerves, the neuromuscular junction, and muscle tissue itself. This anatomical span allows clinicians to distinguish between conditions affecting the nerve (neuropathy), the muscle (myopathy), or the junction between them (neuromuscular junction disorder).

The Centers for Medicare & Medicaid Services (CMS) recognizes EMG and NCS under distinct Current Procedural Terminology (CPT) codes — needle EMG falls under the 95860–95872 range, while nerve conduction studies fall under 95905–95913 — and coverage determinations are governed by Local Coverage Determinations (LCDs) published by Medicare Administrative Contractors (CMS LCD policy framework).

How It Works

EMG and NCS are distinct procedures that are typically performed in sequence during the same appointment, with NCS usually preceding the needle EMG component.

Nerve Conduction Studies — Sequential Steps:

Surface electrode placement: Electrodes are affixed to the skin over the target muscle or nerve pathway.
Electrical stimulation: A brief, controlled electrical pulse is delivered at a defined point along the nerve.
Waveform capture: Recording electrodes capture the compound muscle action potential (CMAP) for motor studies, or the sensory nerve action potential (SNAP) for sensory studies.
Parameter measurement: The technician or physician measures latency (milliseconds from stimulus to response), amplitude (millivolts or microvolts), and conduction velocity (meters per second).
Segment-by-segment mapping: Multiple stimulation sites are tested along the same nerve to identify focal slowing, conduction block, or amplitude drop that pinpoints a lesion site.

Needle EMG — Sequential Steps:

Needle insertion: A fine monopolar or concentric needle electrode is inserted directly into target muscle tissue.
Rest assessment: Spontaneous electrical activity is recorded at rest; normal muscle is electrically silent, while denervated muscle produces fibrillation potentials and positive sharp waves.
Voluntary activation: The patient contracts the muscle at low, moderate, and full effort; the physician analyzes motor unit action potential (MUAP) morphology — duration, amplitude, and phase count.
Recruitment pattern analysis: The rate at which motor units activate and the density of the pattern reveal whether the pathology is neurogenic (reduced recruitment) or myopathic (early, low-amplitude recruitment).

Normal motor conduction velocity in the upper extremities falls in the range of 50–70 meters per second; values below 38 meters per second in the median nerve, for example, are consistent with demyelinating pathology (AANEM practice guidelines).

Common Scenarios

EMG and NCS are ordered across a wide range of clinical presentations. The most frequently evaluated conditions include:

Carpal tunnel syndrome: Focal slowing of median nerve conduction at the wrist is the single most common electrodiagnostic finding in the United States, with AANEM estimating the condition affects approximately 3–6% of the adult population.
Peripheral neuropathy: Diffuse length-dependent slowing or amplitude loss in NCS helps differentiate axonal neuropathy (reduced amplitude, preserved velocity) from demyelinating neuropathy (markedly slowed velocity). This distinction directly informs treatment decisions for conditions such as peripheral neuropathy.
Radiculopathy: Needle EMG revealing fibrillation potentials in a myotomal distribution — muscles sharing a single nerve root — localizes a disk herniation or compressive lesion to a specific spinal level.
Neuromuscular junction disorders: Repetitive nerve stimulation at 3 Hz producing a decremental CMAP response greater than 10% across the first 5 stimuli supports a diagnosis of myasthenia gravis or related neuromuscular disorders.
Amyotrophic lateral sclerosis (ALS): The Awaji criteria, an international electrodiagnostic standard published in 2008, allow fasciculation potentials identified by EMG to substitute for fibrillation potentials in ALS diagnosis, increasing sensitivity particularly in the early bulbar stage. More detail on this condition is available at the ALS topic page.
Plexopathies and mononeuropathies: NCS across the brachial or lumbosacral plexus, combined with needle sampling, localizes traumatic, compressive, or inflammatory injury to specific nerve trunks or cords.

The broader landscape of neurological diagnostic procedures — including how electrodiagnostic testing fits among imaging and other studies — is covered in the neurological conditions overview.

Decision Boundaries

EMG and NCS carry well-defined diagnostic limits that affect clinical interpretation:

What EMG/NCS cannot detect:
- Central nervous system pathology (brain, spinal cord above the anterior horn cell) — findings in these regions are electrically silent to EMG unless lower motor neuron involvement coexists.
- Small-fiber neuropathy affecting unmyelinated C fibers and thinly myelinated Aδ fibers, because standard NCS only measures large myelinated fiber function. Skin punch biopsy for intraepidermal nerve fiber density is the accepted complementary test in this setting.
- Subclinical or very early nerve injury before Wallerian degeneration has progressed sufficiently to produce spontaneous potentials — typically 3 to 4 weeks post-injury.

EMG vs. NCS as distinct instruments:

Feature	Nerve Conduction Study (NCS)	Needle EMG
Target structure	Peripheral nerve (motor or sensory)	Muscle and motor unit
Electrode type	Surface (non-invasive)	Needle (invasive)
Primary parameters	Latency, velocity, amplitude	MUAP morphology, recruitment, spontaneous activity
Best at detecting	Demyelination, focal nerve lesions	Axonal loss, myopathy, neuromuscular junction disease
Pain level	Mild electrical sensation	Moderate discomfort from needle insertion

Safety classifications: AANEM categorizes EMG/NCS as low-risk procedures. Absolute contraindications are limited to needle EMG in patients with documented bleeding disorders or therapeutic anticoagulation at levels that significantly elevate bleeding risk, in which case the procedure may be deferred or modified. There is no ionizing radiation exposure. Implanted cardiac devices (pacemakers, defibrillators) require coordination with the managing cardiologist before surface electrical stimulation is applied, per AANEM safety standards (AANEM safety statement).

The neuromuscular medicine fellowship pathway is the formal subspecialty training route for physicians who perform and interpret these studies at an advanced level.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)